Biodexa Launches Global Early Access Program for eRapa for FAP Patients

Through Strategic Partnership with Tanner Pharma Group

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early Access Program and Named Patient prescribing. This initiative gives clinicians who treat FAP patients the opportunity to prescribe this investigational medicine outside of a clinical trial for the first time.

The program will be open to clinicians globally, for appropriate patients and subject to local legislation and the availability of government or private funding. As part of this initiative and underscoring its long-term commitment to the therapy area, Biodexa will also be generating Real World Data to further expand the understanding of the issues faced by FAP patients in their daily lives.